4.5 Article

Looking beyond pulmonary disease in COVID-19: A lesson from patients with cystic fibrosis

Journal

MEDICAL HYPOTHESES
Volume 147, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.mehy.2020.110481

Keywords

COVID-19; Cystic fibrosis; Endothelial dysfunction; Pulmonary disease; SARS-CoV-2 infection

Ask authors/readers for more resources

Research suggests that focusing on endothelial dysfunction rather than respiratory disease in COVID-19 infection could be key in identifying therapeutic methods that stabilize the endothelium instead of the lungs.
Coronavirus disease 2019 (COVID-19) caused more than 52.775.271 million confirmed cases, 1.293.106 deaths, globally, and afflicted 208 countries, areas, or territories; and almost three months have passed since the World Health Organisation (WHO) declared COVID-19 as a pandemic. Despite the dramatic and global impact of the Coronavirus, the knowledge about the SARS-CoV-2 infection has been improved remarkably. Herein, we provided the rationale for SARS-CoV-2 infection as endothelial dysfunction rather than respiratory disease. Accordingly, we strongly invited the researchers to look beyond pulmonary injury and shift their attention from respiratory disease to endothelial disorder. This strategy could be particularly relevant to identifying therapeutic weapons stabilizing the endothelium rather than the lungs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available